App1: An Antiphagocytic Protein That Binds to Complement Receptors 3 and 2

Paola Stano, Virginia Williams, Maristella Villani, Eugene S. Cymbalyuk, Asfia Qureshi, Yuxiang Huang, Giulia Morace, Chiara Luberto, Stephen Tomlinson and Maurizio Del Poeta

_J Immunol_ 2009; 182:84-91; doi: 10.4049/jimmunol.182.1.84

http://www.jimmunol.org/content/182/1/84

References

This article _cites 42 articles_, 15 of which you can access for free at:

http://www.jimmunol.org/content/182/1/84.full#ref-list-1

Subscription

Information about subscribing to _The Journal of Immunology_ is online at:

http://jimmunol.org/subscription

Permissions

Submit copyright permission requests at:

http://www.aai.org/About/Publications/JI/copyright.html

Email Alerts

Receive free email-alerts when new articles cite this article. Sign up at:

http://jimmunol.org/alerts
App1: An Antiphagocytic Protein That Binds to Complement Receptors 3 and 2

Paola Stano, Virginia Williams, Maristella Villani, Eugene S. Cymbalyuk, Asfia Qureshi, Yuxiang Huang, Giulia Morace, Chiara Luberto, Stephen Tomlinson, and Maurizio Del Poeta

In previous studies, we showed that the pathogenic fungus Cryptococcus neoformans (Cn) produces a specific and unique protein called antiphagocytic protein 1 (App1), which inhibits phagocytosis of Cn by alveolar macrophages (AMs). Phagocytosis of Cn by AMs occurs mainly through a complement- or Ab-mediated mechanism. Among AM receptors, complement receptor 3 (CR3) and FcγR are the most common receptors involved in the phagocytic process. Because App1 inhibits phagocytosis of complement- but not Ab-coated erythrocytes, we investigated the role of CR3 in App1-macrophage interactions. We found that App1 binds to CR3 and if CR3 is absent from the surface of AMs, its antiphagocytic action is lost. When we investigated whether App1 would also bind to other complement receptor(s), we found that App1 does bind to complement receptor 2 (CR2) in a dose-dependent manner. In certain lymphoma cell lines, cellular proliferation is stimulated by complement through CR2, providing a potential use of App1 as a proliferation inhibitor of these cells. Initially discovered as an antiphagocytic protein regulating CR3-mediated innate immunity, App1 may also play a key role in the regulation of acquired immunity, because CR2 is mainly localized on B cells. The Journal of Immunology, 2009, 182: 84–91.

Antiphagocytic protein 1 (App1) is an antiphagocytic protein produced by the fungus Cryptococcus neoformans (Cn), an environmental human pathogen causing a life-threatening meningoencephalitis in immunocompromised patients. Upon inhalation, Cn interaction with alveolar macrophages (AMs) is the key for containment of the infection in the lung or dissemination of fungal cells through the bloodstream to the CNS. During the late 1980s and early 1990s, studies in the laboratory of B. Bolan˜os at the University of Puerto Rico (San Juan, Puerto Rico) identified and purified a Cn cytoplasmic factor involved in the inhibition of phagocytosis of fungal cells by mammalian macrophages. These early studies resulted in the partial isolation and purification from crude cytoplasmic extract of a 20-kDa protein.

Because of such unique biological function, this protein was named App1. In recent years, we rediscovered App1 as a downstream target of the Cn sphingolipid pathway and showed that App1 was found in the culture supernatant of a Cn culture (1). We next demonstrated that App1 is transcriptionally controlled by inositol phosphoryl ceramide synthase through the production of diacylglycerol and the activating transcription factor 2 (1–3).

In our ongoing epistasis analysis to understand the mechanism(s) by which App1 inhibits phagocytosis, we produced rApp1 and created a Cn strain in which App1 was deleted (Cn Δapp1). The Cn Δapp1 is increasingly phagocytosed by macrophages compared with the Cn wild-type (WT) strain. Pharmacological treatment with increasing concentrations of rApp1 protein blocks the internalization of Cn in a dose-dependent manner (1). Because we found that rApp1 inhibits phagocytosis of complement- and not Ab-coated erythrocytes, we proposed that App1 exerts its antiphagocytic action against Cn by inhibiting complement- and not Ab-mediated phagocytosis.

The complement system is a collection of circulating and cell membrane proteins that play an important role in host defense against microbes. The most abundant complement protein in the plasma is C3. Its first cleavage product, C3b, is further degraded to iC3b, C3c, and C3dg, which serve as ligands for selective complement receptors on leukocytes (4, 5). Complement receptor 3 (CR3) is present on the surface of monocytes, macrophages, and dendritic cells, and is composed of two subunits, CD11b and CD18, and it mainly serves as the receptor for internalization of iC3b-opsonized microbes, such as Cn (reviewed in Refs. 6 and 7).

Among other complement receptors, complement receptor 2 (CR2; CD21) also binds iC3b, although its main ligands are C3d and C3dg. Instead of being localized on phagocytic cells, CR2 is mainly localized on the surface of B cells and is involved in B cell activation and differentiation (8, 9). In Burkitt’s lymphoma, a non-Hodgkin lymphoma of high malignancy produced by the EBV infection of B cells, CR2 is particularly important because not only does it serve as receptor for EBV, but, through binding with its
complement ligand(s), it stimulates tumor cellular proliferation (10).

In this study, we show that App1 binds to CR3 and the inhibition of phagocytosis by rApp1 is completely lost in AMs in which CR3 is absent. We show that CR3 is absent in AMs, either actively or passively, perhaps through capsule shedding. We also show that App1 binds to CR2, providing a new potential role of App1 in the adaptive immune response against Cn.

Materials and Methods

Strains, cell cultures, and growing medium

The following strains were used in this study: the Cn variety gattii serotype A strain H99 (WT), Δapp1 knockout strain, and the Δapp1rec strain, which were created from H99 strain. Cn variety gattii serotype B strain MMRL 1336; Cn variety neoformans serotype C strain MMRL 1343; and Cn variety neoformans serotype D strain JECC1. Cn strains were routinely grown on yeast peptone dextrose medium. The Δapp1 strain was created through a double-crossover event replacing the APP1 gene open reading frame with the ADE2 gene. PCR and Southern and Western blotting were used to confirm the absence of the APP1 gene and App1 protein (1). The Δapp1rec strain was created by reintroducing the APP1 gene back into the Δapp1 strain and specifically in the App1 locus. This was demonstrated by Southern analysis (1). The absence of App1 in the Δapp1 strain did not have an effect on capsule formation, melanin production, or growth at 30°C, 37°C (pH 7.0 or 4.0) (1). Lysing enzyme from Tricoderma harziai was from Sigma-Aldrich.

Chinese hamster ovary (CHO) cell lines stably transfected with human CR3 (CD18/CD11b), human CD14, or neomycin (NEO) resistance vector alone were a gift from D. Golenbock (Boston Medical Center, Boston, MA). Expression of CR3 and CD14 was determined by flow cytometry (data not shown). CHO cell lines were cultured in a MEM (Life Technologies; catalogue 12571) with 10% heat-inactivated FBS (Life Technologies; catalogue 10092-147) in G418 (final concentration 0.4 mg/ml) and 1% penicillin-streptomycin. rApp1 protein and phosphoglucone isomerase from methanocarina (mpGI) protein were produced by D. Fedarova in the Medical University of South Carolina Center of Biomedical Research Excellence Protein Core Facility (Charleston, SC) directed by C. Davies.

Production and purification of rApp1 and mAbs and polyclonal Ab (pAb) against App1

Large-scale production of rApp1 protein was performed as follows. The pBAD-His-App1 vector generated previously (1) was used for protein expression. Escherichia coli TOP10 cells containing pBAD-His-App1 plasmid were inoculated into 10 ml of Luria-Bertani medium supplemented with 50 μg/ml ampicillin and grown overnight at 37°C, 220 rpm. Then, 2 ml of cells was each inoculated into 5 × 1 L of Luria-Bertani medium with 50 μg/ml ampicillin and grown to an OD600 of 0.6 – 0.8. The culture was induced with 20 μg/ml 1-arabinose and grown overnight at 30°C, 220 rpm. Cells were collected by spinning at 4500 rpm for 10 min, and the cell pellet was frozen at −80°C for 2 h. Frozen cells were then thawed and resuspended in cold buffer A (10 mM Tris-HCl, 0.15 M NaCl, 1% Triton X-100, and 1 mM EDTA). Next, 1 mM PMSF was freshly added just before sonication on ice. The mixture was then incubated with 0.2 mg/ml lysozyme at room temperature for 1 h and then centrifuged at 10,000 rpm for 40 min at 4°C. Inclusion bodies were washed twice with 25 ml of buffer A, once with 25 ml of buffer B (10 mM Tris-HCl, 0.15M NaCl, and 1 mM EDTA), and once with 25 ml of distilled water. The inclusion bodies were incubated overnight in 10 ml of 8 M urea at 4°C on a rotary shaker. The next morning, the supernatant was centrifuged at 10,000 rpm for 30 min at 4°C, then added to 1 L of buffer C (50 mM KH2PO4, 20 mM Tris, 0.15M NaCl, 10% glycerol, and 2 mM β-ME (pH 8.0)) to allow for refolding of App1. The protein solution was loaded onto a pre-equilibrated buffer (buffer D, 20 mM Tris-HCl, 0.5M NaCl, and 2 mM 2-ME (pH 7.8)) HisTrap HP 5-ml column (GE Healthcare) using a peristaltic pump P-1 (GE Healthcare). The column was washed with 100% buffer D, followed by 95% D and 2% E (20 mM Tris-HCl, 0.5 M NaCl, 0.5 M Imidazole, and 2 mM 2-ME (pH 7.8)) and then 85% D and 15% E. App1 was eluted with 40% D and 60% E. The fractions containing App1 were dialyzed twice with 1 L of buffer F (50 mM Tris-HCl/0.15 M NaCl/5% glycerol/2 mM 2-ME (pH 7.9)) at 4°C, and then concentrated.

For the production of App1 full-length and truncated forms, we used the pGEX-6P-3 plasmid (Amersham Biosciences), which contains the GST tag. First, a PCR fragment was generated using primers App1-BamH1-F and App1–3′-rPSET/GPX, 5′-TTC GAA TTC TCT AAT CAT CAA TGT TCG CAG CTC-3′, using the pBAD-His-App1 plasmid as a template. The resulting 568-bp fragment was digested with BamHI and EcoRI and cloned into the BamHI- and EcoRI-Restricted pGEX-6P-3 plasmid, generating pGEX-App1 (1–181) plasmid. Next, a series of plasmid carrying truncated forms of App1 proteins were generated for studying epitope recognition by Abs. Through a series of PCR and subcloning procedures, we created the following plasmids: pGEX-App1 (1–33), pGEX-App1 (33–90), pGEX-App1 (90–140), and pGEX-App1 (140–181), as indicated.

Production of CR2

Soluble CR2 was produced as follows: CR2-Fc2-FH cells were added to a cell culture dish containing 10 ml of medium (made up of 500 ml of DMEM, 50 ml of dialyzed and inactivated FBS, 10 ml of glucose synthesis expression medium supplement, 28 μl of 100 μM l-methionine sulfonamide, and 5 ml of penicillin-streptomycin). When the cells reached 90–100% confluency, they were trypsinized and split into five-cell culture dishes each with 10 ml of medium. Upon 100% confluency, the cells were trypsinized, centrifuged at 800 rpm for 5 min, and resuspended into 500 ml of medium. A total of 2 × 250 ml was then added to 2 × 235-cm2 Corning Glass CellBIND surface-expanded surface flask and incubated for 4–7 days at 37°C, 5% CO2, and 100% relative humidity. Soluble CR2 was harvested by filtering the supernatant through a 0.22-μm Express Plus Stericup filter, then loading it onto a PBS-equilibrated HiTrap FF column containing anti-CR2 Ab using a peristaltic pump P-1. The column was washed with PBS, and the protein was eluted with 0.1 M glycine-HCl (pH 2.7). The fractions containing the protein were concentrated using an Amicon Centricon Plus-20 filter device with a 5000 Da molecular weight cutoff and the same device used for buffer exchange to PBS.

App1-CR3-binding assay

CHO cells expressing CR3 (CHO-CR3), CD14 (CHO-CD14), or empty plasmid (CHO-NEO) were a gift from D. Golenbock (Boston Medical Center, Boston, MA). CHO-CR3, CHO-CD14, or CHO-NEO were grown as monolayers in six-well culture dishes at a density of 0.025 × 106. When cells were confluent, wells were aspirated dry, washed with 10% PBS medium, and then resuspended in 1 ml of 10% PBS medium using 0.2 μg rApp1/ml or with 1 μg of rApp1/ml and Ab anti-human CD11b monoclo-

Phagocytosis assay

Ex vivo phagocytosis was performed in C57BL/6J (CR3+/+) and/or B6.129S4-ftgam1Imbb1/v (CR3−/-) mice. The CR3−/- are isogenic of C57BL/6J mice. Briefly, mice were anesthetized with an intraperitoneal injection of 0.1 ml of xylazine/ketamine mixture, containing 95 mg of ketamine/kg body weight and 5 mg of xylazine/kg body weight. Then, Cn WT, Δapp1, or Δapp1rec strains were inoculated intranasally. Three mice were used for each Cn strain. After 2 h, mice were euthanized by CO2 inhalation, and AMs and yeast cells were collected by broncoalveolar lavage. Cells were then centrifuged at 1200 rpm, and resuspended in 30 μl of 1/× Laemmli sample buffer (Bio-Rad). Samples were then analyzed by a Western blot using anti-App1 4-GH Ab. For saturation experiments, the same protocol was followed with CHO-CR3 cells, with increasing concentrations of App1 from 0 to 1000 μg/ml. The resulting Western blot was semiquantified using LabWorks software to measure the total raw density of each band while subtracting the background.
serum, 1% t-glutamine, and 100 U/ml penicillin-streptomycin, and incubated at 37°C (5% CO₂) for 2 h. Nonadherent AMs were removed by washing the wells with warm medium.

Cn cells were prepared, as previously described. Briefly, from a fresh overnight culture, Cn cells were washed twice with sterile PBS (pH 7.4) and resuspended in DMEM with or without 10% fresh mouse serum. Next, 6 × 10⁵ Cn cells together with different concentrations of rApp1 protein (as indicated) were added to AMs and plates were incubated at 37°C (5% CO₂) for 2 h. Nonattached Cn cells were removed by washing with PBS. Cells were then fixed with ice-cold methanol and stained with Giemsa (Sigma-Aldrich). The phagocytic indexes (defined as the number of internalized yeast cells/100 macrophages) were determined for each set of experimental conditions. Eight fields per experiment were counted and averaged. Results represent the geometric means ± SDs of the phagocytic indexes obtained from three different experiments per strain.

**App1-CR2-binding assay: ELISA**

The assay was performed in a 96-well microtiter plate (Maxisorp NUNC). First, the wells were coated with 50 µl/well of 5 µg/ml extracellular domain of mouse CR2 in coating buffer (5 mM Na₂CO₃, 35 mM NaHCO₃ (pH 9.6)) and incubated overnight at 4°C. The plate was then blocked with 2% BSA in PBS, incubated 2 h at 37°C, and then washed three times with PBST/0.1% Tween 20 (PBST). A total of 1 µg/50 µl/well rApp1 in 1% BSA and 1% PBS was added and incubated overnight at 4°C. After three washes with PBST, 50 µl of anti-App1 mAb/well, diluted 1/20 with 1% BSA/PBS, was added and incubated 2 h at 37°C. The plate was washed three times with PBST and incubated with 50 µl of mouse secondary Ab anti-IgG HRP/well (Jackson ImmunoResearch Laboratories) diluted 1/5000 with 1% BSA/PBS, for 2 h at 37°C. After three washes with PBST, the color was developed with 50 µl/well 3', 5'-tetramethylbenzidine (Sigma-Aldrich). The reaction was then stopped with 50 µl of 2 M H₂SO₄, and the plate was read at 450 nm with a VersaMax plate reader. For competition assay, different dilutions of mAb 4-6H and 3-11F were preincubated with 1 µg/50 µl rApp1 for 1 h at 37°C, and then added to the CR2-coated wells and incubated overnight at 4°C. Plates were then processed as described above.

**Immunoprecipitation of App1**

A starter culture of H99 was prepared in yeast peptone dextrose (10 ml) and incubated for 24 h at 30°C, 250 rpm. A 1/40 dilution in yeast nitrogen base was then conducted, and the culture was incubated 24 h at 30°C, 250 rpm. The culture was centrifuged at 2800 rpm, and the cells were washed three times in 0.5 M NaCl/50 mM EDTA, then resuspended in sterile water and incubated 1 h at 37°C, with occasional mixing. Following incubation, the cells were centrifuged at 2800 rpm and resuspended in spheroplastic solution (1 ml) consisting of 1 M sorbitol, 0.1 M sodium citrate (pH 5.8), and 0.01 M EDTA with or without 10 µg of lysing enzyme. Cells were incubated for 3.5 h at 37°C with occasional mixing. The sample was then centrifuged at 1000 rpm for 10 min, and the resulting supernatant was centrifuged again for 20 min at 10,000 × g at 4°C. The supernatant was carefully transferred to a sterile tube and placed on ice. A total of 50 µl of protein G-Sepharose resin slurry/1 ml of supernatant was added to precleared the lysate. The sample was rocked at 4°C for 1 h, and then centrifuged at 10,000 × g at 4°C for 1 min. The supernatant was transferred to a sterile tube and placed on ice. Anti-App1 pAb 545 (1/50 dilution) and 50 µl/mml protein G-Sepharose resin slurry were added to the supernatant, and the sample was rocked at 4°C for 24 h. Following centrifugation at 10,000 × g, 4°C for 1 min, the supernatant was removed and the resin was washed twice with spheroplastic solution (without lysing enzyme) before being used for SDS-PAGE and Western blot.

**Capture ELISA**

The assay was performed in a 96-well microtiter plate (Maxisorp; Nunc). First, the wells were coated with 50 µl/well of 5 µg/ml extracellular domain of mouse CR2 in coating buffer (5 mM Na₂CO₃, 35 mM NaHCO₃ (pH 9.6)) and incubated overnight at 4°C. The plate was then blocked with 2% BSA in PBS, incubated 2 h at 37°C, and then washed three times with PBST/0.1% Tween 20 (PBST). A total of 1 µg/50 µl/well rApp1 in 1% BSA and 1% PBS was added and incubated overnight at 4°C. After three washes with PBST, 50 µl of anti-App1 mAb/well, diluted 1/20 with 1% BSA/PBS, was added and incubated 2 h at 37°C. The plate was then blocked with 2% BSA in PBS, incubated 2 h at 37°C, and then washed three times with PBST. Varying concentrations of rApp1 in 1% BSA in PBS were used for standard curve. A total of 50 µl of medium (treated or untreated with lysing enzyme) was added and incubated overnight at 4°C. The reaction was then stopped with 50 µl of 2 M H₂SO₄, and the plate was read at 450 nm with a VersaMax plate reader. The experiments were performed twice.

**Statistics**

Statistical analysis was performed using two-tailed Student’s t-test.

**Results**

**Production and characterization of anti-App1 Abs**

To study the antiphagocytic function of App1 in vivo and in vitro, we produced anti-App1 mAb and pAb (Fig. 1). These tools were necessary to study the function of App1 at the molecular level. We produced two mouse mAb (mAb 4-6H and mAb 3-11F) and two

---

**FIGURE 1.** Production of anti-App1 mAb and pAb. A. Western blot analysis of App1 production in Cn WT Δapp1, Δapp1 + APP1 reconstituted strains, C. albicans, E. coli, cervical human cancer HeLa cell line, and S. cerevisiae using mAb 4-6H and pAb 544. B. Production of App1 by different Cn serotypes (A–D), as indicated, grown in glucose (Glu) or glyceral (Gly) as a sole carbon source. C. App1 protein is found in the medium and can be immunoprecipitated using pAb 544. Treatment with lysing enzyme increases the amount of App1 in the medium. Sup, supernatant; IP, immunoprecipitation. D. Capture ELISA of App1 present in the medium before (−) and after (+) treatment with lysing enzyme.
rabbit pAb (pAb 544 and pAb 545). Fig. 1A illustrates that mAb 4-6H and pAb 544 react with App1 produced by WT Cn or Δapp1 + APP1 reconstituted strain, but not with Δapp1 strain. App1 appears to be a Cn-specific protein because it is not found in Candida albicans, E. coli, the cervical human cancer HeLa cell line, or Saccharomyces cerevisiae. Comparing the production of App1 among different serotypes of Cn, App1 is mainly produced by Cn serotype A strain compared with other serotypes. Interestingly, its production is significantly up-regulated when cells are grown in presence of glycerol compared with glucose as the sole carbon source (Fig. 1B). These results suggest that App1 is a Cn-specific protein, which is differentially expressed by different Cn serotypes.

To exert its antiphagocytic function, Cn App1 should be either secreted and/or exposed on the surface of Cn (capsule/cell wall). Because we already found that App1 is present in the supernatant (1), we wondered whether digesting Cn cells with lysing enzyme would enrich its presence in the medium. Lysing enzyme from T. harzianum hydrolyzes poly(1–3)-glucose of the yeast glucan-releasing cell wall and capsule materials in the medium. Unexpectedly, we found that upon treatment with lysing enzyme, App1 protein is enriched in the medium compared with untreated cells (Fig. 1, C and D), suggesting that App1 may interact with capsule and/or cell wall materials.

App1 binds to CHO cells expressing CR3

Because in our previous studies we showed that rApp1 blocks the phagocytosis of complement- and not Ab-coated erythrocytes, we reasoned that App1 would inhibit the complement-mediated phagocytosis of Cn. Among complement receptors, CR3 (CD11b/CD18) on the surface of AMs plays a major role in the attachment and internalization of many fungi, including C. albicans (11), Blastomyces dermatitidis (12), and Cn (13–15). Thus, we decided to focus our attention on CR3.

To begin studying the App1-CR3 interaction, we tested whether App1 would interact with a CHO cell line expressing human CR3 (CHO-CR3). As negative controls, we used CHO cells expressing CD14 (CHO-CD14) or an empty vector (CHO-NEO). The expression of the indicated receptor on CHO cells was confirmed and quantified by flow cytometry analysis (data not shown). rApp1 was incubated with CHO-CR3, CHO-CD14, and CHO-NEO, as indicated in Fig. 2A. Cells were then washed and collected, and membrane proteins were loaded for SDS-PAGE and Western blot analysis using anti-App1 mAb 4-6H. As illustrated in Fig. 2A, rApp1 binds to CHO-CR3, but not to CHO-CD14 or CHO-NEO.

As mentioned above, CR3 is comprised of two subunits: CD11b and CD18. Thus, we wondered whether App1 would bind to CD11b and/or CD18. As shown in Fig. 2A, coinubcation with anti-CD11b Ab totally abrogates the interaction between rApp1 and CHO-CR3. Coincubation with anti-CD18 Ab did not inhibit rApp1 binding to CHO-CR3 (data not shown). These results suggest that rApp1 may bind to the CD11b subunit of CR3.

To demonstrate that Cn nApp1 binds to CR3, we incubated the cell lysate obtained from Cn WT or Δapp1 strain with CHO-CR3 cell line. After incubation, total proteins were extracted and analyzed by Western blot using mAb 4-6H. As illustrated in Fig. 2B, nApp1 was detected only when total proteins obtained from Cn WT, and not Δapp1, were incubated with CHO-CR3, indicating that nApp1 interacts with CR3.

To further prove the binding between App1 and CR3, we tested whether the binding was saturable. CHO cells expressing CR3 were incubated with increasing amounts of App1. As shown in Fig. 3, we found that the binding between App1 and CR3 is saturable, as the binding curve plateaus. Proving the binding is saturable further proves the App1 and CR3 interaction.

The antiphagocytic action of App1 depends on the presence of CD11b

To establish the role of CD11b in Cn phagocytosis, we sought to perform an ex vivo phagocytosis using CR3<sup>+/−</sup> WT (C57BL/6J) and CR3<sup>−/−</sup> mice in which CD11b is deleted (Jackson B6.129S4-itgam<sup>tm1Myd</sup>-J). The CR3<sup>−/−</sup> mouse model is an isogenic model of C57BL/6J. Thus, we measured the phagocytic index of Cn WT, Δapp1, and Δapp1 + APP1 (Δapp1<sup>Prec</sup>) strains after 2 h of lung
FIGURE 4. The antiphagocytic action of App1 is lost when CD11b subunit is absent in AMs. A, Ex vivo phagocytosis of Cn WT, Δapp1, and Δapp1 + APP1 (Δapp1Rec) strains after 2 h of intranasal inoculation of C57BL/6J (CR3+/+) or B6.129S4-itgam−/−/J (CR3−/−) mice, in which the CD11b (and not the CD18) subunit is absent. Phagocytosis of Cn Δapp1 strain increases in CR3−/− AMs compared with Cn WT (+, p < 0.05), whereas it does not in CR3+/− AMs. B, Treatment with rApp1 restores WT phenotype in CR3+/− AMs, whereas rApp1 treatment does not affect phagocytosis when CD11b subunit is absent from the surface of AMs (CR3−/−) (+, p < 0.05). C, Treatment with rApp1 has no effect on phagocytosis when Cn cells are not opsonized with serum regardless of the presence of CR3.

infection. As shown in Fig. 4A, CR3+/+ AMs readily phagocytosed Cn Δapp1 compared with WT or Δapp1Rec strain. Interestingly, when CD11b is absent (CR3−/−), the Δapp1 strain is phagocytosed by AMs similarly to the WT or the Δapp1Rec strains. These results suggest that CD11b is required to efficiently internalize Δapp1.

Next, we tested the effect of rApp1 on Cn phagocytosis by CR3+/+ and CR3−/− AMs in vitro. Whereas treatment with rApp1 decreases phagocytosis in CR3+/+ AMs of Cn Δapp1 in a dose-dependent manner, treatment with rApp1 did not affect the internalization of Cn WT, Δapp1, or Δapp1Rec strains by AMs lacking CD11b (Fig. 4B), and this effect is lost when Cn cells are not opsonized with serum (Fig. 4C). These results suggest that App1 exerts its antiphagocytic action through the CD11b subunit of CR3 by blocking the interaction of iC3b on the surface of Cn with CR3. As expected, the overall phagocytosis of Cn WT strain in CR3−/− was decreased compared with CR3+/+, although not completely abolished, because Cn is also phagocytosed through receptors other than complement (7, 16).

App1 binds to CR2 in vitro, and this binding is inhibited by iC3b

Thus, we examined the App1-CR2 interaction using an ELISA. The CR2 N-terminal short-consensus repeats responsible for the C3d-CR2 binding (short consensus repeat 1–4, residues 1–257 of mature protein, GenBank M35684) were expressed and purified, as described in Materials and Methods. The N terminus mouse rCR2 was absorbed onto an ELISA plate, rApp1 was added, and rCR2-rApp1 interaction was examined using mAb against App1. As shown in Fig. 5A, we found a dose- and time-dependent interaction between rApp1 and rCR2, whereas no interaction was observed between CR2 and BSA or CR2 and mPGI, a His-tagged control protein.

FIGURE 5. App1 binds to CR2. A, CR2 recombinant protein was coated onto an ELISA plate, and App1, mPGI, or BSA was added at different concentrations, as indicated. Binding was detected using mAb 4-6H against rCR2. Significant binding of rApp1 to CR2 is observed at 1, 5, and 10 μg (*, CR2-App1 vs CR2-BSA; p < 0.05). B, Coincubation of App1 and iC3b (in equimolar concentrations) to CR2 blocks App1-CR2 binding almost completely (*, p < 0.001).
protein used to ensure that the effect seen for rApp1 is specific. Importantly, preincubation of an equimolar concentration iC3b completely abolished the binding of rApp1 to rCR2 (Fig. 5B). These results suggest that, in addition to CR3, rApp1 interacts also with CR2.

App1 epitope recognition by anti-App1 Abs

Both mAb and pAb anti-App1 were tested for App1 epitope recognition. The rApp1 full-length and different App1-truncated forms were loaded on a SDS-PAGE, and Western blot was performed using either mAb 4-6H (Fig. 6A) or 3-11F (Fig. 6B), or pAb rabbit 544 (data not shown). The results show that mAb 4-6H recognizes a domain present within 33–90, whereas mAb 3-11F recognizes a domain present within 140–181. Polyclonal 544 and S45 recognizes all domains, as expected (data not shown).

Because of these difference between mAb 4-6H and mAb 3-11F, we wondered whether a preincubation of rApp1 with its mAb would interfere with CR2 binding. Interestingly, preincubation with anti-App1 mAb 4-6H inhibited rApp1-rCR2 interaction by 50%, whereas incubation with anti-App1 mAb 3-11F did not show any inhibition of App1-CR2 interaction (Fig. 6C). These results suggest that rApp1 binds to CR2 and possibly, but not exclusively, with a domain within aa 33–90.

Discussion

Cn is a facultative intracellular pathogen and, as such, it has the ability to survive intra- and extracellularly. Whereas the identification of specific fungal factor(s) or molecule(s) that allows Cn to survive intracellularly is the focus of intensive investigations, little is known about the factors that would allow Cn to escape phagocytosis and survive extracellularly, such as in alveolar space, bloodstream, and extracellular tissues. The production of the polysaccharide capsule provides effective protection to extracellular yeast cells against AMs and other host immune cells, because the capsule material negatively affects diverse aspects of the host immune response (22, 25). In addition to the polysaccharide capsule, Cn produces certain glycosphingolipid(s), such as glucosylceramide, which is required for its growth in extracellular environments characterized by high CO2 and alkaline pH (26) and to transport Cn polysaccharide outside fungal cells (27).

In recent years, we identified a Cn factor (App1) that specifically regulates the internalization of Cn by AMs in vitro and ex vivo, and, most likely, also during the infection because App1 was found in sera of AIDS patients affected with cryptococcosis (1). When we investigated whether App1 would regulate pathogenicity of Cn in murine models of cryptococcosis, we found the intriguing result that, compared with Cn WT strain, app1 mutant is hypervirulent in immunocompromised mouse models lacking T and NK cells (Tge26), but hypovirulent in complement-deficient model (A/1cr) (1) or immunocompetent mouse models, such as CBA/J and C57BL/6 (data not shown). We hypothesized that the App1 phenotype is due to the unique ability of the protein to modulate phagocytosis. If more Cn cells will be internalized by AMs (lower production of App1) and AMs cannot effectively kill them, phagocytosis can be considered an opportunity of the fungus to cause disease. Under this condition, the host could benefit from a switch of fungal cells from the intra- to the extracellular environment by specifically delivering App1 in the infected lung.

In this work, we studied how App1 blocks phagocytosis of Cn, and the results led us to explore whether App1 would bind to complement receptors other than CR3, such as CR2. CR3 is an opsonic receptor present on the surface of phagocytic cells. It recognizes complement fragment iC3b deposited on microbial surface, such as Cn, and it regulates phagocytosis. CR3 is comprised of two subunits, CD11b, which binds iC3b, and fungal β glucan and CD18, which, in the case of Cn, glucuronoxylomannan, which is the major component of the Cn polysaccharide capsule. CR2 is found on the surface of B and follicular dendritic cells (28), and in many subsets of T cells, including CD4+ and CD8+ (29, 30). CR2 can bind many complement fragments, such as C3b, iC3b, C3dg, and C3d (6, 31, 32). It is also called CD21 and, instead of being involved in the regulation of phagocytosis, CR2 plays a key role in the enhancement of humoral immune responses (33, 34) by linking the binding of specific ligands to signal transduction events mediated by other members of the CD21/CD19 complex on B lymphocytes (35, 36). Expression of CR2 is also required on follicular dendritic cells for robust humoral immune response, probably by mediating Ag trapping or cell-cell interactions in lymphoid organs (17).

The interaction of App1 with CR3 is shown by using CHO cells expressing human CR3. App1 interacts with CHO-CR3, but not with CHO-CD14 or CHO-NEO cells. The total absence of this interaction when anti-CD11b Ab is coincubated suggests that App1 binds to CD11b. There is still a possibility that App1 binds to CD18 and that inhibition of anti-CD11b is due to steric hindrance.
App1 BLOCKS CR3-MEDIATED PHAGOCYTOSIS

... by Dr. Christopher Davies.

References


